C8 MediSensors Gains CE Mark Approval for the C8 MediSensors Optical Glucose Monitor(TM) System for People with Diabetes
2 Pages
English

C8 MediSensors Gains CE Mark Approval for the C8 MediSensors Optical Glucose Monitor(TM) System for People with Diabetes

Downloading requires you to have access to the YouScribe library
Learn all about the services we offer

Description

C8 MediSensors Gains CE Mark Approval for the C8 MediSensors Optical Glucose Monitor(TM) System for People with Diabetes PR Newswire SAN JOSE, California, October 25, 2012 SAN JOSE, California, October 25, 2012 /PRNewswire/ -- A new non-invasive continuous glucose monitor is approved for marketing in Europe C8 MediSensors, Inc. (http://www.c8medisensors.com) has today announced it received CE Mark approval for its Optical Glucose Monitor System, allowing the device, a new non-invasive continuous glucose monitor (nCGM), to be marketed in Europe. http://www.c8medisensors.com The comprehensive, 10-year Diabetes Control and Complications Trial (DCCT) clearly demonstrated that individuals with type 1 diabetes who kept blood glucose levels as close to normal as possible for as long as possible had less chance of developing disease-related complications. The DCCT found that the risk of eye disease was reduced by [1]76%, kidney disease by 50% and nerve disease by 60%. Since that time, other studies have confirmed the importance of tight glycaemic control with minimal glucose excursions in reducing disease-related complications not [2-6]only in type 1 diabetes, but also in type 2. In addition, a large number of studies have shown that continuous glucose [7-19]monitors (CGM) can improve glycaemic control with reduced risk of hypoglycaemia. CGMs are adjunct devices that are intended to complement finger stick blood glucose tests.

Subjects

Informations

Published by
Reads 28
Language English
C8 MediSensors Gains CE Mark Approval for the C8 MediSensors Optical Glucose Monitor(TM) System for People with Diabetes
PR Newswire SAN JOSE, California, October 25, 2012
SAN JOSE, California,October 25, 2012/PRNewswire/ --
A new non-invasive continuous glucose monitor isapproved for marketing in Europe
C8 MediSensors, Inc. (http://www.c8medisensors.com) has today announced it received CE Mark approval for its Optical Glucose Monitor System, allowing the device, a new non-invasive continuous glucose monitor (nCGM), to be marketed in Europe.
http://www.c8medisensors.com The comprehensive, 10-year Diabetes Control and Com plications Trial (DCCT) clearly demonstrated that individuals with type 1 diabetes who kept blood glucose levels as close to normal as possible for as long as possible had less chance of developing disease-related complications. The DCCT found that the risk of eye disease was [1] reduced by 76%, kidney disease by 50% and nerve disease by 60%. Since that time, other studies have confirmed the importance of tight glycaemic control with minimal glucose excursions in reducing disease-related complications [2-6] not only in type 1 diabetes, but also in type 2. In addition, a large number of studies have shown that continuous [7-19] glucose monitors (CGM) can improve glycaemic control with reduced risk of hypoglycaemia.
CGMs are adjunct devices that are intended to complement finger stick blood glucose tests. Traditional CGMs rely [20] on a needle sensor inserted under the skin, which can cause pain or discomfort, and pose a risk of infection. In contrast, theC8 MediSensors Optical Glucose Monitor Systemharnesses the power of light to measure glucose levels. Using Raman spectroscopy, a beam of light is shone into the skin and the resulting vibrations of glucose molecules are measured to give a glucose reading; all achieved via a small, pain-free portable monitor, discreetly worn under clothes against the skin.
For added convenience these readings are stored and sent wirelessly to the user's smartphone for glucose readings at a glance, providing the wearer with a continuous picture of glucose dynamics throughout the day. A [1] good understanding of glucose levels is invaluable in managing diabetes and improving patient outcomes. In clinical studies, the C8 MediSensors monitor was found to have accuracy comparable to earlier versions of invasive CGMs when those systems were first introduced, but with less pain and less risk of infection.
"C8 MediSensors was co-founded by a father trying to help his son living with diabetes, and as a company, we remain dedicated to helping those with the disease," said Paul Zygielbaum, CEO of C8 MediSensors. "CE Mark approval is a landmark step for this unique technology. Our team is hugely excited to be working to make nCGM and theOptical Glucose Monitor SystemEurope."available throughout
TheC8 MediSensors Optical Glucose Monitor Systemwill initially be available for purchase online via the C8 MediSensors website,http://www.c8medisensors.com.
TheC8 MediSensors Optical Glucose Monitor SystemIt is contraindicated in pregnancyis an adjunct device. and for those under 18 years of age, as well as in individuals with very light or very dark skin tones, peripheral vascular disease or individuals who smoke.
-ends-
Notes to editors:
About C8 MediSensors
C8 MediSensors is the leader in non-invasive continuous glucose monitoring. Headquartered inSan Jose CA, C8 MediSensors' breakthrough patent-protected technology gives people with diabetes a continuous view of their glucose levels, without the pain, inconvenience and high cost of invasive continuous glucose monitoring. Visit http://www.c8medisensors.com.
Additional background information on 'Diabetes and continuous glucose monitoring' and 'C8 MediSensors and the Optical Glucose Monitor' are available from the European media contacts below.
This document contains forward-looking statements. Any statements contained in this document that are not
statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements relating to the company's anticipated product sales and financing needs. These forward-looking statements are based upon the company's current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks associated with market conditions, customer demand for the product, and risks and uncertainties associated with the company's business and finances in general. You are cautioned not to place undue reliance on these forward-looking statem ents, which speak only as of the date of this document. The com pany does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.
References
1. The Diabetes Control and Complications Trial Res earch Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.N Engl J Med 1993;329(14):977-86 2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998;352(9131):837-53 3. Monnier L, Colette C, Boegner C, et al. Continuo us glucose monitoring in patients with type 2 diabetes: Why? When? Whom?Diabetes Metab2007;33(4):247-52 4. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.JAMA2006;295(14):1681-7 5. Hirsch IB, Abelseth J, Bode BW, et al. Sensor-au gmented insulin pump therapy: results of the first randomized treat-to-target study.Diabetes Technol Ther2008;10(5):377-83 6. Ceriello A. The glucose triad and its role in co mprehensive glycaemic control: current status, future management. Int J Clin Pract2010;64(12):1705-11 7. Beck RW, Buckingham B, Miller K, et al. Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes.Diabetes Care2009;32(11):1947-53 8. Anderson J, Effect on glycemic control by short- and long-term use of continuous glucose monitoring in clinical practice.J Diabetes Sci Technol2011;5(6):1472-8 9. Bailey TS, Zisser HC, Garg SK. Reduction in hemo globin A1C with real-time continuous glucose monitoring: results from a 12-week observational study.Diabetes Technol Ther2007;9(3):203-10 10. Chico A, Vidal-Ríos P, Subirà M, Novials A. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control.Diabetes Care2003;26(4):1153-7 11. Garg S, Jovanovic L. Relationship of fasting an d hourly blood glucose levels to HbA1c values: safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor.Diabetes Care 2006;29(12):2644-9 12. Garg S, Zisser H, Schwartz S, et al. Improvemen t in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial.Diabetes Care2006;29(1):44-50 13. Kaufman FR, Gibson LC, Halvorson M, et al. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects.Diabetes Care2001;24(12):2030-4 14. Garg SK, Kelly WC, Voelmle MK, et al. Continuou s home monitoring of glucose: improved glycemic control with real life use of continuous glucose sensors in adult subjects with type 1 diabetes.Diabetes Care2007;30(12):3023-5 15. Chase HP, Beck RW, Xing D, et al. Continuous glucose monitoring in youth with type 1 diabetes: 12-month follow-up of the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial.Diabetes Technol Ther2010;12(7):507-15 16. Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study.Pediatrics2003;111(5 Pt 1):933-8 17. De Block C, Manuel-y-Keenoy B, Van Gaal L. A review of current evidence with continuous glucose monitoring in patients with diabetes.J Diabetes Sci Technol2008;2(4):718-27 18. Vazeou A. Continuous blood glucose monitoring in diabetes treatment.Diabetes Res Clin Pract2011;93 (Suppl.1):S125-30 19. Harman-Boehm I. Continuous glucose monitoring in type 2 diabetes.Diabetes Res Clin Pract2008;82 (Suppl.2):S118-21 20. Vaddirajuet al.Technologies for Continuous Glucose Monitoring: Current Problems and Future Promises.J Diabetes Sci Technol2010;4(6):1540-1562